Navigation Links
MIGENIX Reports Third Quarter Fiscal Year 2008 Financial Results
Date:3/13/2008

--------------------------------------------

Unattributed Expenses

Personnel $0.7 $0.7 $2.2 $2.0

Patent costs 0.1 0.2 0.7 0.6

Other 0.2 0.2 0.8 0.8

--------------------------------------------

Total Unattributed Expenses $1.0 $1.1 $3.7 $3.4

--------------------------------------------

Total Research & Development

Expenses $1.5 $2.1 $5.0 $5.6

--------------------------------------------

--------------------------------------------

(1) Before amortization expense, technology and license acquisition

costs, and write-downs of intangibles assets.

(2) Value of $0.0 million represents $nil to ~$50,000 in expenses during

the period.

Our Omiganan programs are being advanced by development and commercialization partners (Cadence Pharmaceuticals and Cutanea Life Sciences).

Celgosivir program costs were $0.3 million in Q3/08 (Q3/07: $0.4 million) and were $1.0 million for YTD Fiscal 2008 (YTD Fiscal 2007: $1.1 million).

Costs in the MX-2401 program in Q3/08 were $0.1 million (Q3/07: $0.4 million) and were $0.2 million for YTD Fiscal 2008 (YTD Fiscal 2007: $1.0 million). The decrease in Q3/08 and YTD Fiscal 2008 MX-2401 costs is principally due to higher cost manufacturing activity in Q3/07 and YTD Fiscal 2007 in preparation for the GLP studies started in April 2007.

Research and development costs not allocated to programs were $1.0 million in Q3/08 (Q3/07: $1.1 million) and were $3.7 million for YTD Fiscal 2008 (YTD Fiscal 2007: $3.4 million). The approximate $0.3 million increase in these unallocated research and development
'/>"/>

SOURCE MIGENIX Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16

Related biology technology :

1. MIGENIX Third Fiscal Quarter 2008 Financial Results Conference Call & Webcast Notification
2. MIGENIX releases CEO message #22
3. MIGENIX to Add 600mg Daily Celgosivir Dose to Phase II Viral Kinetics Study
4. MIGENIX Reports Second Quarter Fiscal Year 2008 Financial Results
5. MIGENIX Second Fiscal Quarter 2008 Financial Results Conference Call & Webcast Notification
6. MIGENIX to Present at the Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference
7. MIGENIX Reports First Quarter Fiscal Year 2008 Financial Results
8. MIGENIX to Present Positive Celgosivir Viral Resistance Data at International HCV Meeting
9. MIGENIX First Fiscal Quarter 2008 Financial Results Conference Call & Webcast Notification
10. Nventa Biopharmaceuticals Reports Full Year 2007 and Fourth Quarter Financial Results
11. Micromet, Inc. Reports Fourth Quarter and Full Year 2007 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2015)... ... September 02, 2015 , ... Whitehouse Laboratories is excited ... Pharma Ed Resources upcoming educational seminar and training session on Extractable & Leachable ... conference will provide Updates & Case Studies on the Latest Compliance Implications of ...
(Date:9/2/2015)... ... September 02, 2015 , ... The TS5-Q is designed for ... content, to analysis of athletic performance. Producing high-resolution slow-motion video , the ... to process with the naked eye. , Slow motion sequences are commonly ...
(Date:9/1/2015)... , September 2, 2015 ... auf die Forschung und Entwicklung neuartiger Therapien ... chronisch-entzündliche Darmerkrankungen und Reizdarm konzentriert, erhält vom ... dass sein neues Medikament patentiert wird. Das ... Allergien bei Kindern verhindert und Entzündungen vorbeugt.   ...
(Date:9/1/2015)... The American Brain Tumor Association (ABTA) is now accepting ... program. LOIs are due no later than Wednesday, October ... Discovery Grants are one-year, $50,000 grants that fund high risk/high ... or treatment paradigms for adults and children with brain ... earliest stages, in the hopes that it spurs additional ...
Breaking Biology Technology:Whitehouse Laboratories to Participate in Pharm Ed Resources Extractables, Leachables, & Elemental Impurities Educational Seminar 2Whitehouse Laboratories to Participate in Pharm Ed Resources Extractables, Leachables, & Elemental Impurities Educational Seminar 3Fastec Introduces the Quad-HD TS5-Q High-Speed Camera 2Fastec Introduces the Quad-HD TS5-Q High-Speed Camera 3Das Patent von Swecure zur Verhinderung von Allergien bei Kindern wird in den USA zugelassen 2American Brain Tumor Association Seeks Innovative Concepts For Discovery Research Grants 2
... , , , , , ... service for large insert vectors such as BACs, cosmids and fosmids. ... high quality results with , rapid turnaround including: , ... Unique library construction strategies , Patented SPRI technology ...
... , , , , ... uses a single protocol to purify a variety of high , ... and produces high quality templates. The single protocol, ease of automation ... for all template , purification needs. , ...
... , , , , , , ... up system capable , of purifying amplicons as small as 100bp. ... protocol requiring no centrifugation , or filtration steps. The protocol can ... 384-well formats. , , ...
Cached Biology Technology:FULL LENGTH INSERT SEQUENCING 2COSMCPREP HIGH AND LOW COPY PLASMID PURIFICATION 2COSMCPREP HIGH AND LOW COPY PLASMID PURIFICATION 3AMPURE PURIFICATION SYSTEM 2AMPURE PURIFICATION SYSTEM 3
(Date:8/20/2015)... The wearable technology market has traditionally ... healthy. However, wearable technology has the potential to ... improve diagnostic capabilities and therapeutic outcomes. Today, Leaf ... Technologies Conference 2015 , where Barrett Larson ... healthcare.    "Over the past decade, ...
(Date:8/19/2015)... Aug. 19, 2015  VOXX International Corporation (Nasdaq: ... entered into a Definitive Agreement to purchase the ... authentication market leader EyeLock through an acquiring entity.  ... a controlling interest in the acquiring entity. The ... of due diligence.  Expanding on its existing supply ...
(Date:8/17/2015)...  NXT-ID, Inc. (NASDAQ: NXTD ) ("NXT-ID" or ... growing mobile commerce market and creator of the Wocket® ... 2015. The new marketing campaign is being spearheaded by ... Group ( http://amplitudemarketing.com/ ) and TPMG ( http://tmpg.com/ ). ... retail driven marketing and brand awareness and has a ...
Breaking Biology News(10 mins):Leaf Healthcare Releases Video from Wearable Technology Conference on New Applications for Wearables in the Hospital Environment 2Leaf Healthcare Releases Video from Wearable Technology Conference on New Applications for Wearables in the Hospital Environment 3VOXX International Corporation Signs Definitive Agreement To Acquire The Assets And A Controlling Interest Of Biometric Leader EyeLock 2VOXX International Corporation Signs Definitive Agreement To Acquire The Assets And A Controlling Interest Of Biometric Leader EyeLock 3VOXX International Corporation Signs Definitive Agreement To Acquire The Assets And A Controlling Interest Of Biometric Leader EyeLock 4VOXX International Corporation Signs Definitive Agreement To Acquire The Assets And A Controlling Interest Of Biometric Leader EyeLock 5NXT-ID, Inc. Launches Sales Campaign for Wocket Smart Wallet with Award Winning Marketing Team 2NXT-ID, Inc. Launches Sales Campaign for Wocket Smart Wallet with Award Winning Marketing Team 3
... ON An innovative treatment technology could give cancer ... based at Lawson Health Research Institute and London Health ... testing a therapy with the potential to eradicate cancers ... cancer occur when it spreads from the original tumour ...
... , Dr. Reddy,s studies on the management of sweetpotato ... in that he is searching for the right formula ... pesticides. However, in addition to C. formicarius ... Daealus tuberosus) causing damage in the field and storage ...
... Consortium ( www.concord.org ) has received a $2.5 million ... curricula that model the "textbook of tomorrow." "The ... examples out there still barely scratch the surface of ... better, deeply digital learning experiences for science, mathematics, and ...
Cached Biology News:London researchers lead innovative new cancer treatment study 2The Concord Consortium awarded multi-million dollar Google grant 2
... a direct antibiotic-based selection ... Recombinant selection depends solely ... the need for costly ... and inexpensive process provides ...
These stopping screens are for the biolistic PDS-1000 He and Hepta systems. Supplied as 500 screens....
... Geneious does sequence alignment, 3D structure ... and more; all in a single application. ... several NCBI databases, Uniprot, sort and filter ... how you want it, rapidly searching, filtering ...
... a comprehensive suite of advanced statistics ... to reliably extract biological signals from ... containing thousands of samples, Partek Genomics ... will analyze large data sets on ...
Biology Products: